The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers
Abstract
Summary: The new anticoagulants dabigatran and rivaroxaban can be responsible for haemorrhagic complications. As for any anticoagulant, bleeding management is challenging. We aimed to test the effect of all putative haemostatic agents on the anticoagulant activity of these new drugs using thrombin generation tests. In an ex vivo study, 10 healthy white male subjects were randomised to receive rivaroxaban (20 mg) or dabigatran (150 mg) in one oral administration. After a two weeks washout period, they received the other anticoagulant. Venous blood samples were collected just before drug administration (H0) and 2 hours thereafter. Reversal of anticoagulation was tested in vitro using prothrombin complex concentrate (PCC), rFVIIa or FEIBA® at various concentrations. Rivaroxaban affects quantitative and kinetic parameters, including the endogenous thrombin potential (ETP-AUC and more pronouncedly the thrombin peak), the lag-time and time to peak. PCC strongly corrected ETP-AUC, whereas rFVIIa only modified the kinetic parameters. FEIBA corrected all parameters. Dabigatran specially affects the kinetics of thrombin generation with prolonged lag-time and time to peak. Although PCC increased ETP-AUC, only rFVIIa and FEIBA corrected the altered lag-time. For both anticoagulants, lower doses of FEIBA, corresponding to a quarter to half the dose usually used, have potential reversal profile of interest. In conclusion, some non-specific reversal agents appear to be able to reverse the anticoagulant activity of rivaroxaban or dabigatran. However, clinical evaluation is needed regarding haemorrhagic situations, and a meticulous risk-benefit evaluation regarding their use in this context is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Thrombin generation, a function test of the haemostaticthrombotic system
Al Dieri, R., De Smedt, E., Béguin, S., & Hemker, H. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-07-0408 · Cited by 467
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Hron, G., Kollars, M., Binder, B. R., Eichinger, S., & Kyrle, P. A. (2006) · JAMA · doi:10.1001/jama.296.4.397 · Cited by 381
Wang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Zhou, W., Schwarting, S., Illanes, S., Liesz, A., Middelhoff, M., Zorn, M., Bendszus, M., Heiland, S., van Ryn, J., & Veltkamp, R. (2011) · Stroke · doi:10.1161/strokeaha.111.624650 · Cited by 324
Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002) · Circulation · doi:10.1161/01.cir.0000038501.87442.02 · Cited by 316
The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding
Al Dieri, R., Peyvandi, F., Santagostino, E., Giansily, M., Mannucci, P. M., Schved, J., Béguin, S., & Hemker, H. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613258 · Cited by 290
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
HILLARP, A., BAGHAEI, F., FAGERBERG BLIXTER, I., GUSTAFSSON, K. M., STIGENDAL, L., STEN‐LINDER, M., STRANDBERG, K., & LINDAHL, T. L. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04098.x · Cited by 288
Stassen, J.-M., Priepke, H., Ries, U. J., Hauel, N., & Wienen, W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0183 · Cited by 250
Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.-M., Emmerich, J., Marchand-Leroux, C., Lecompte, T., & Samama, C.-M. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318238c036 · Cited by 246
EHRLICH, H. J., HENZL, M. J., & GOMPERTS, E. D. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00532.x · Cited by 220
Warkentin, T. E., Margetts, P., Connolly, S. J., Lamy, A., Ricci, C., & Eikelboom, J. W. (2012) · Blood · doi:10.1182/blood-2011-11-393587 · Cited by 207
The Use of Dabigatran in Elderly Patients
Legrand, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.314 · Cited by 204
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
LEVI, M., EERENBERG, E., & KAMPHUISEN, P. W. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04432.x · Cited by 170
Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Testa, S., Tiraferri, E., Tosetto, A., Tripodi, A., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-05-0358 · Cited by 159
GEROTZIAFAS, G. T., ELALAMY, I., DEPASSE, F., PERZBORN, E., & SAMAMA, M. M. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02429.x · Cited by 159
Freyburger, G., Macouillard, G., Labrouche, S., & Sztark, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.001 · Cited by 157
Graff, J., von Hentig, N., Misselwitz, F., Kubitza, D., Becka, M., Breddin, H., & Harder, S. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302952 · Cited by 139
Wójcik, C., Schymik, M. L., & Cure, E. G. (2009) · International Journal of Emergency Medicine · doi:10.1007/s12245-009-0125-8 · Cited by 77
Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits
Pragst, I., Dörr, B., Kaspereit, F., et al. (2012) · F1000Research · doi:10.7490/f1000research.1089950.1 · Cited by 13
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Management of bleeding and coagulopathy following major trauma: an updated European guideline
Spahn, D. R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2013) · Critical Care · doi:10.1186/cc12685 · Cited by 977
Metadata
- Authors
- Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012
- Volume
- 108
- Issue
- 08
- Pages
- 217-224
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1940756716
- Cited by
- 501
- References
- 26
- FWCI
- 55.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.